Merit Medical Executive's Share Sale Raises Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 17 2026
0mins
Source: Fool
- Executive Share Sale: Lynne N. Ward, a director at Merit Medical Systems, sold 5,000 shares in an open market transaction valued at approximately $313,000, indicating a significant reduction in her ownership, with direct holdings decreasing by 39% from 12,809 shares to 7,809 shares.
- Transaction Impact Analysis: This sale marks Ward's only open-market transaction in the past year, reflecting a continued reduction in her holdings, and comes at a time when Merit Medical's stock hit a 52-week low of $59.74 on May 12, raising concerns about the company's growth prospects amid macroeconomic pressures.
- Company Financial Overview: Merit Medical Systems reported a trailing twelve-month revenue of $1.54 billion and a net income of $139.34 million, with a workforce of 7,400 employees; despite facing macroeconomic challenges, the company's focus on innovation and procedural efficiency remains a key competitive advantage in the medical device sector.
- Investor Concerns: Following the sale, Ward retains 7,809 shares, suggesting confidence in the company's long-term outlook, even as the sales guidance shows only a slight increase over the previous year, indicating potential growth deceleration that investors should monitor closely.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMSI
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 64.520
Low
90.00
Averages
104.63
High
122.00
Current: 64.520
Low
90.00
Averages
104.63
High
122.00
About MMSI
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merit Medical Elects Scott Ward to Board of Directors
- New Board Member: Merit Medical elected Scott Ward to its Board of Directors during the annual shareholder meeting for a three-year term, reflecting the company's emphasis on diverse and experienced leadership.
- Extensive Industry Experience: With over 40 years in the medical device sector, including senior roles at Medtronic, Ward is expected to significantly impact Merit's strategic development and growth trajectory.
- Committee Appointments: Ward has been appointed to the Governance and Sustainability and Finance and Operating Committees, underscoring the company's trust in his strategic insights and decision-making capabilities.
- Commitment to Innovation: Ward expressed respect for Merit's dedication to innovation and patient service, indicating that his contributions will likely enhance the company's long-term growth and market expansion efforts.
See More
Merit Medical Executive's Share Sale Raises Concerns
- Executive Share Sale: Lynne N. Ward, a director at Merit Medical Systems, sold 5,000 shares in an open market transaction valued at approximately $313,000, indicating a significant reduction in her ownership, with direct holdings decreasing by 39% from 12,809 shares to 7,809 shares.
- Transaction Impact Analysis: This sale marks Ward's only open-market transaction in the past year, reflecting a continued reduction in her holdings, and comes at a time when Merit Medical's stock hit a 52-week low of $59.74 on May 12, raising concerns about the company's growth prospects amid macroeconomic pressures.
- Company Financial Overview: Merit Medical Systems reported a trailing twelve-month revenue of $1.54 billion and a net income of $139.34 million, with a workforce of 7,400 employees; despite facing macroeconomic challenges, the company's focus on innovation and procedural efficiency remains a key competitive advantage in the medical device sector.
- Investor Concerns: Following the sale, Ward retains 7,809 shares, suggesting confidence in the company's long-term outlook, even as the sales guidance shows only a slight increase over the previous year, indicating potential growth deceleration that investors should monitor closely.
See More
Merit Medical to Participate in 2026 Bank of America Health Care Conference
- Conference Participation: Merit Medical will participate in the Bank of America Health Care Conference from May 12-14, 2026, with management scheduled for a fireside chat on May 12 at 3:00 PM PT, highlighting the company's leadership in healthcare technology.
- Live Webcast: The fireside chat will be accessible via the company's investor relations website, allowing global investors to stay updated on the latest developments, which is expected to enhance investor interest and confidence in the company.
- Company Background: Founded in 1987, Merit Medical specializes in the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly impacting cardiology, radiology, and oncology.
- Global Team: With over 800 sales and clinical support personnel and approximately 7,600 employees worldwide, Merit Medical demonstrates strong operational capabilities and market reach in the global medical device sector.
See More
Merit Medical Systems Reports Strong Q1 2026 Earnings and Strategic Acquisition
- Revenue Growth: Merit Medical reported total revenue of $381.9 million in Q1 2026, reflecting a 7% year-over-year increase, with U.S. sales up 6.8% and international sales up 3%, indicating robust market performance.
- Acquisition Expansion: The company acquired View Point Medical for $140 million, with $90 million paid in cash, which is expected to triple the annual addressable procedure opportunity for its oncology business, enhancing competitive positioning.
- Profitability Improvement: Q1 net income reached $56.7 million, or $0.94 per share, exceeding guidance by $3.7 million, while the non-GAAP operating margin hit 19.7%, marking the highest in the company's history and reflecting effective management execution.
- Future Outlook: The company anticipates total revenue growth of 6.3% to 7.8% for 2026, with non-GAAP EPS projected between $4.01 and $4.15, demonstrating confidence in future growth despite facing tariff and geopolitical risks.
See More
Merit Medical Systems to Release Q1 2026 Financial Results
- Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
- Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
- Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
See More
Merit Medical Acquires View Point Medical for $140M
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for a total transaction value of $140 million, with $90 million paid upfront and $25 million due on the first and second anniversaries of the closing date, thereby enhancing its competitive position in the medical device market.
- Product Innovation Enhancement: View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers, which improve tissue localization, allowing surgeons to quickly detect and visualize tissue markers during biopsies, thus enhancing precision in breast cancer surgeries and reducing re-excision rates.
- Future Growth Projections: Merit Medical projects a revenue growth of 6% to 8% for 2026, and this acquisition will help strengthen its global platforms while divesting DualCap to optimize resource allocation and enhance profitability.
- Industry Impact Analysis: This acquisition not only enhances Merit’s product portfolio in the medical technology sector but also has the potential to drive technological advancements in breast cancer treatment by improving surgical precision and reducing patient reoperation risks, highlighting its strategic significance.
See More
Merit Medical Elects Scott Ward to Board of Directors
- New Board Member: Merit Medical elected Scott Ward to its Board of Directors during the annual shareholder meeting for a three-year term, reflecting the company's emphasis on diverse and experienced leadership.
- Extensive Industry Experience: With over 40 years in the medical device sector, including senior roles at Medtronic, Ward is expected to significantly impact Merit's strategic development and growth trajectory.
- Committee Appointments: Ward has been appointed to the Governance and Sustainability and Finance and Operating Committees, underscoring the company's trust in his strategic insights and decision-making capabilities.
- Commitment to Innovation: Ward expressed respect for Merit's dedication to innovation and patient service, indicating that his contributions will likely enhance the company's long-term growth and market expansion efforts.
See More
Merit Medical Executive's Share Sale Raises Concerns
- Executive Share Sale: Lynne N. Ward, a director at Merit Medical Systems, sold 5,000 shares in an open market transaction valued at approximately $313,000, indicating a significant reduction in her ownership, with direct holdings decreasing by 39% from 12,809 shares to 7,809 shares.
- Transaction Impact Analysis: This sale marks Ward's only open-market transaction in the past year, reflecting a continued reduction in her holdings, and comes at a time when Merit Medical's stock hit a 52-week low of $59.74 on May 12, raising concerns about the company's growth prospects amid macroeconomic pressures.
- Company Financial Overview: Merit Medical Systems reported a trailing twelve-month revenue of $1.54 billion and a net income of $139.34 million, with a workforce of 7,400 employees; despite facing macroeconomic challenges, the company's focus on innovation and procedural efficiency remains a key competitive advantage in the medical device sector.
- Investor Concerns: Following the sale, Ward retains 7,809 shares, suggesting confidence in the company's long-term outlook, even as the sales guidance shows only a slight increase over the previous year, indicating potential growth deceleration that investors should monitor closely.
See More
Merit Medical to Participate in 2026 Bank of America Health Care Conference
- Conference Participation: Merit Medical will participate in the Bank of America Health Care Conference from May 12-14, 2026, with management scheduled for a fireside chat on May 12 at 3:00 PM PT, highlighting the company's leadership in healthcare technology.
- Live Webcast: The fireside chat will be accessible via the company's investor relations website, allowing global investors to stay updated on the latest developments, which is expected to enhance investor interest and confidence in the company.
- Company Background: Founded in 1987, Merit Medical specializes in the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly impacting cardiology, radiology, and oncology.
- Global Team: With over 800 sales and clinical support personnel and approximately 7,600 employees worldwide, Merit Medical demonstrates strong operational capabilities and market reach in the global medical device sector.
See More
Merit Medical Systems Reports Strong Q1 2026 Earnings and Strategic Acquisition
- Revenue Growth: Merit Medical reported total revenue of $381.9 million in Q1 2026, reflecting a 7% year-over-year increase, with U.S. sales up 6.8% and international sales up 3%, indicating robust market performance.
- Acquisition Expansion: The company acquired View Point Medical for $140 million, with $90 million paid in cash, which is expected to triple the annual addressable procedure opportunity for its oncology business, enhancing competitive positioning.
- Profitability Improvement: Q1 net income reached $56.7 million, or $0.94 per share, exceeding guidance by $3.7 million, while the non-GAAP operating margin hit 19.7%, marking the highest in the company's history and reflecting effective management execution.
- Future Outlook: The company anticipates total revenue growth of 6.3% to 7.8% for 2026, with non-GAAP EPS projected between $4.01 and $4.15, demonstrating confidence in future growth despite facing tariff and geopolitical risks.
See More
Merit Medical Systems to Release Q1 2026 Financial Results
- Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
- Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
- Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
See More
Merit Medical Acquires View Point Medical for $140M
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for a total transaction value of $140 million, with $90 million paid upfront and $25 million due on the first and second anniversaries of the closing date, thereby enhancing its competitive position in the medical device market.
- Product Innovation Enhancement: View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers, which improve tissue localization, allowing surgeons to quickly detect and visualize tissue markers during biopsies, thus enhancing precision in breast cancer surgeries and reducing re-excision rates.
- Future Growth Projections: Merit Medical projects a revenue growth of 6% to 8% for 2026, and this acquisition will help strengthen its global platforms while divesting DualCap to optimize resource allocation and enhance profitability.
- Industry Impact Analysis: This acquisition not only enhances Merit’s product portfolio in the medical technology sector but also has the potential to drive technological advancements in breast cancer treatment by improving surgical precision and reducing patient reoperation risks, highlighting its strategic significance.
See More
